These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22687143)

  • 61. MRI Clinical Ratings and Cognitive Function in a Cross-Sectional Population Study of Dementia: The Cache County Memory Study.
    Tsui-Caldwell YHW; Farrer TJ; McDonnell Z; Christensen Z; Finuf C; Bigler ED; Tschanz JT; Norton MC; Welsh-Bohmer KA
    J Prev Alzheimers Dis; 2019; 6(2):100-107. PubMed ID: 30756116
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
    Suh GH; Ju YS; Yeon BK; Shah A
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Longitudinal changes in awareness over 36 months in patients with mild Alzheimer's disease.
    Vogel A; Waldorff FB; Waldemar G
    Int Psychogeriatr; 2015 Jan; 27(1):95-102. PubMed ID: 25075811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Association Between Circulating Inflammatory Markers and the Progression of Alzheimer Disease in Norwegian Memory Clinic Patients With Mild Cognitive Impairment or Dementia.
    Hazen J; Vistnes M; Barca ML; Eldholm RS; Persson K; Brækhus A; Saltvedt I; Selbæk G; Engedal K; Knapskog AB
    Alzheimer Dis Assoc Disord; 2020; 34(1):47-53. PubMed ID: 31414991
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of premorbid IQ and education on progression of Alzheimer's disease.
    Pavlik VN; Doody RS; Massman PJ; Chan W
    Dement Geriatr Cogn Disord; 2006; 22(4):367-77. PubMed ID: 16954693
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia.
    Borda MG; Aarsland D; Tovar-Rios DA; Giil LM; Ballard C; Gonzalez MC; Brønnick K; Alves G; Oppedal K; Soennesyn H; Vik-Mo AO
    J Am Geriatr Soc; 2020 Oct; 68(10):2257-2263. PubMed ID: 32738062
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cerebral volume loss, cognitive deficit and neuropsychological performance: comparative measures of brain atrophy: I. Dementia.
    Bigler ED; Neeley ES; Miller MJ; Tate DF; Rice SA; Cleavinger H; Wolfson L; Tschanz J; Welsh-Bohmer K
    J Int Neuropsychol Soc; 2004 May; 10(3):442-52. PubMed ID: 15147601
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.
    Bettermann K; Arnold AM; Williamson J; Rapp S; Sink K; Toole JF; Carlson MC; Yasar S; Dekosky S; Burke GL
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):436-44. PubMed ID: 21236699
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery.
    Kim J; Na HK; Byun J; Shin J; Kim S; Lee BH; Na DL
    Dement Geriatr Cogn Disord; 2017; 44(1-2):105-117. PubMed ID: 28768247
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study.
    Steinberg M; Corcoran C; Tschanz JT; Huber C; Welsh-Bohmer K; Norton MC; Zandi P; Breitner JC; Steffens DC; Lyketsos CG
    Int J Geriatr Psychiatry; 2006 Sep; 21(9):824-30. PubMed ID: 16955439
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer's disease.
    Chou PS; Wu MN; Chou MC; Chien I; Yang YH
    Geriatr Gerontol Int; 2017 Oct; 17(10):1544-1550. PubMed ID: 27862810
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease.
    Barnes J; Bartlett JW; Wolk DA; van der Flier WM; Frost C
    J Alzheimers Dis; 2018; 64(2):631-642. PubMed ID: 29914016
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 77. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
    Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
    J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anosognosia in Alzheimer's disease: association with patient characteristics, psychiatric symptoms and cognitive deficits.
    Kashiwa Y; Kitabayashi Y; Narumoto J; Nakamura K; Ueda H; Fukui K
    Psychiatry Clin Neurosci; 2005 Dec; 59(6):697-704. PubMed ID: 16401246
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.
    Poulin SP; Bergeron D; Dickerson BC;
    J Alzheimers Dis; 2017; 60(2):483-493. PubMed ID: 28869463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.